ArticleJournal of asthma and allergy2026
Medical Unmet Needs in Uncontrolled Asthma Despite GINA Step 4/5 Treatment in Poland.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma is a heterogeneous chronic respiratory disease characterized by symptoms such as wheezing, shortness of breath, cough, and bronchial obstruction confirmed in spirometry. According to the Polish National Health Fund (NHF), in 2023 there were 2.07 million patients with asthma (International Classification of Diseases, ICD-10 codes J45, J46) in Poland. Despite guideline-based treatment recommended by the Global Initiative for Asthma (GINA) at steps 4 and 5, a substantial proportion of patients remain uncontrolled, leading to significant clinical and societal burden. Objective: This study aimed to identify the prevalence of uncontrolled asthma among adults receiving GINA step 4/5 therapy in Poland and to characterise the most common medical unmet needs (MUNs). Methods: We analyzed prescription data from the IQVIA™ Longitudinal Prescription Data (LRx) database covering approximately 55% of Polish pharmacies between November 2023 and October 2024. Adult patients (≥20 years) with GINA step 4/5 asthma were identified based on treatment patterns, including inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), long-acting muscarinic antagonists (LAMA), oral corticosteroids (OCS), and biologics. MUNs were defined as: (1) annual OCS exposure >500 mg, (2) ≥2 exacerbations requiring high-dose OCS rescue medication, and (3) excessive short-acting beta-agonist (SABA) use (>3 packs/year). Results: Among 1.44 million adult asthma patients, 372,905 (26%) were classified as GINA step 4/5. Of these, 64,235 (17.2%) exhibited at least one MUN. High OCS exposure was most frequent (54% of MUN patients), followed by ≥2 exacerbations (38%) and SABA overuse (45%). Conclusion: Despite advanced therapy, a significant proportion of GINA step 4/5 asthma patients in Poland remain uncontrolled. Addressing these unmet needs requires optimized treatment strategies, improved patient education, and broader access to biologic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.